麻豆精选

Ambitious project to develop low-cost genome sequencing for pathogens known and unknown

Project will build on research that helped diagnostic labs to adopt sequencing capacity for COVID-19 and permit characterisation of future infectious threats.

Changing how the world tracks emerging viruses | University 麻豆精选

University 麻豆精选, 2025

A low-cost genome sequencing technique that was used by thousands of laboratories globally to spot COVID-19 variants of concern will now be extended to cover all pathogens, known or unknown, in an ambitious new project launched today.

The ARTIC 2.0 project brings together an international collaboration led by the University 麻豆精选. The team includes researchers from the Democratic Republic of the Congo, Ghana and Kenya with expertise in responding to numerous viral threats using genomic surveillance including recent outbreaks of Ebola virus and Mpox in Africa.

The ARTIC project will develop the underlying technology for the surveillance of emerging pathogens around the world. ARTIC 2.0 will work alongside the Africa CDC, Asia Pathogen Genomics Initiative and the WHO International Pathogen Surveillance Network to ensure that processes can then be rolled out worldwide.

Genomic surveillance is a powerful tool in the fight against infectious diseases. By analysing the genetic makeup of pathogens like viruses or bacteria, scientists can track the spread of outbreaks and understand their evolution over time. This information can help public health officials predict future outbreaks, develop targeted treatments, and implement effective control measures. It also aids in tracing the source of an outbreak and understanding how it has been transmitted between different populations.

ARTIC-2 will help to realise the ambition that any laboratory, anywhere in the world could access affordable, high-quality genomic sequencing for their work.

Professor Nicholas Loman, lead researcher for ARTIC-2

Easy access to genomic sequencing will enable public health laboratories around the world to respond more quickly and effectively to outbreaks of new and emerging viruses as well as better understand the mutations that occur randomly which lead to immune evasion or increased resistance to treatments.

A key element of the ARTIC 2.0 programme will be the continued development of a low-cost laboratory protocols and equipment that significantly reduce the cost of sequencing. The team are focused on reducing the cost of sequencing to under 拢10 per sample, reducing costs by focusing on open-source methods and reducing the reliance on expensive proprietary equipment and reagents. Lower costs allow more labs to perform sequencing where it is badly needed such as in low and middle income countries (LMIC) and the global south.

The project will also improve the way in which data is shared between researchers through a new initiative called Pathoplexus. Better data sharing can significantly improve outbreak response and public health decision-making as it allows for more accurate monitoring and tracking of disease transmission, enabling early detection and control efforts.

The team also aims to rationalise the approach to develop a knowledge engine that will link all aspects of existing processes and tools with new learning to provide a universal and global toolkit for surveillance of pathogenic threats.

Professor Nick Loman, Professor of Microbial Genomics and Bioinformatics at the University 麻豆精选 and lead researcher for ARTIC 2.0 said:

鈥淎RTIC 2.0 will help to realise the ambition that any laboratory, anywhere in the world could access affordable, high-quality genomic sequencing for their work. During the global pandemic, sequencing was one of the most important tools at our disposal to understand how the coronavirus was changing to help inform development of new treatments and vaccines as well as public health policies.

"With funding from Wellcome to develop ARTIC 2.0 we can develop a universal, global toolkit and learning platform that means any endemic virus or pathogen around the world can be sequenced quickly and cheaply.鈥

Dr Placide Mbala Kingebeni, National Institute of Biomedical Research in the Democratic Republic of Congo and co-researcher on the project said:

"The ARTIC 2.0 initiative represents a major leap forward in our ability to detect and respond to infectious disease threats in real time. By expanding genomic surveillance beyond high-consequence viruses to include endemic and emerging pathogens, we are strengthening our capacity to act swiftly and effectively in the face of new outbreaks.

"This funding will enable us to build a more robust and adaptable response system; one that is accessible, cost-effective, and capable of guiding public health action where and when it is needed most."

Real world testing

To ensure that the programme is easy to adopt anywhere in the world, the ARTIC 2.0 programme will also develop locally accessible bioinformatics support to help determine best ways to tackle pathogens as part of this project.

ARTIC 2.0 will build on the success of the initial project that developed an integrated field-deployable viral sequencing system which could be rapidly deployed to study outbreaks and epidemics anywhere in the world. The same lab-in-a-suitcase concept will be further developed in ARTIC 2.0 for a variety of potential uses including surveillance of known endemic pathogens including zoonotic viruses such as Mpox and Marburg.

Natsuko Imai, Research Lead, Epidemics at Wellcome, said:

"Genomic sequencing is crucial for understanding the circulation, spread, and evolution of pathogens, providing essential insights to protect public health. By making this technology accessible and affordable, researchers in regions affected by diseases such as mpox, mosquito-borne viruses and TB can conduct in-situ sequencing, dramatically enhancing their ability to inform tailored public health strategies.

"Developing in-country capabilities and expertise strengthens local health systems, enabling rapid responses to emerging and endemic diseases to protect vulnerable communities, both locally and worldwide."

Notes for editors

For media enquiries please contact Tim Mayo, Press Office, University 麻豆精选, tel: +44 (0)7815 607 157.

Partners involved in ARTIC 2

  • University 麻豆精选
  • University of Cambridge
  • University of Edinburgh
  • Institut National pour la Recherche Biomedicale (INRB), DRC
  • KEMRI-Wellcome, Kenya
  • West African Centre for Cell Biology of Infectious Pathogens, University of Ghana
  • Swiss Tropical and Public Health Institute
  • Simon Fraser University (Vancouver, Canada)
  • Wellcome Trust

About the University 麻豆精选

  • The University 麻豆精选 is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham, including researchers, educators and more than 40,000 students from over 150 countries.
  • England’s first civic university, the University 麻豆精选 is proud to be rooted in of one of the most dynamic and diverse cities in the country. A member of the Russell Group and a founding member of the Universitas 21 global network of research universities, the University 麻豆精选 has been changing the way the world works for more than a century.

About Wellcome

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health.

Related videos